Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/07/25
End: 05/31/27
Due: 05/31/28
Phase: N/A
Priority: Normal
Start: 09/06/21
End: 07/31/25
Due: 07/31/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors | NCT06877533 | iTeos Belgium SA | user2@example.com | None | 2025-04-07 | 2027-05-31 | 2028-05-31 | - | - | 2025-07-14 |
| Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors | NCT05060432 | iTeos Belgium SA | user2@example.com | None | 2021-09-06 | 2025-07-31 | 2026-07-31 | - | - | 2025-07-14 |